Treatment of chronic graft-versus-host disease with clofazimine

Blood

Volumn 89, Issue 7, 1997, Pages 2298-2302

  Lee, Stephanie J ^b   Wegner, Scott A ^b   McGarigle, Carol J ^b   Bierer, Barbara E ^b   Antin, Joseph H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMYCOBACTERIAL AGENT; BUSULFAN; CLOFAZIMINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; STEROID;

ADULT; APLASTIC ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HUMAN; HYPERPIGMENTATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; MALE; MYELODYSPLASTIC SYNDROME; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; WHOLE BODY RADIATION;

EID: 0030945010     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.7.2298     Document Type: Article

References (40)

1. Atkinson K: Chronic graft-versus-host disease. Bone Marrow Transplant 5:69, 1990
2. Wingard JR, Piantadosi S, Vogelsang GB, Farmer ER, Jabs DA, Levin LS, Beschorner WE, Cahill RA, Miller DF, Harrison D, Saral R, Santos GW: Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 74:1428, 1989
3. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, Hackman R, Tsoi M-S, Storb R, Thomas ED: Chronic graft-versus-host syndrome in man. A long-term clinico-pathologic study in 20 Seattle patients. Am J Med 69:204, 1980
4. Sullivan KM, Witherspoon RP, Storb R, Deeg HJ, Dahlberg S, Sanders JE, Appelbaum FR, Doney KC, Weiden P, Anasetti C, Loughran TP, Hill R, Shields A, Yee G, Shulman H, Nims J, Strom S, Thomas ED: Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 72:555, 1988
5. Sullivan KM, Witherspoon RP, Storb R, Weiden P, Flournoy N, Dahlberg S, Deeg HJ, Sanders JE, Doney KC, Appelbaum FR, McGuffin R, McDonald GB, Meyers J, Schubert MM, Gauvreau J, Shulman HM, Sale GE, Anasetti C, Loughran TP, Strom S, Nims J, Thomas ED: Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: Prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 72:546, 1988
6. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, Corio RL, Levin LS, Colvin OM, Wingard JR, Santos GW: Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 326:1055, 1992
7. Parker PM, Chao N, Nademanee A, O'Donnell MR, Schmidt GM, Snyder DS, Stein AS, Smith EP, Molina A, Stepan DE, Kashyap A, Planas I, Spielberger R, Somlo G, Margolin K, Zwingenberger K, Wilsman K, Negrin RS, Long GD, Niland JC, Blume KG, Forman SJ: Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 86:3604, 1995
8. Summerfield GP, Bellingham AJ, Bunch C, Woodrow JC: Successful treatment of chronic cutaneous graft-versus-host-disease (GVHD) with penicillamine. Clin Lab Haematol 5:313, 1983
9. Owsianowski M, Gollnick H, Siegert W, Schwerdtfeger R, Orfanos CE: Successful treatment of chronic graft-versus-host disease with extracorporeal photopheresis. Bone Marrow Transplant 14:845, 1994
10. Kapoor N, Pelligrini AE, Copelan EA, Cunningham I, Avalos BR, Klein JL, Tutschka PJ: Psoralen plus ultraviolet A (PUVA) in the treatment of chronic graft versus host disease: Preliminary experience in standard treatment resistant patients. Semin Hematol 29:108, 1992
11. Eppinger T, Ehninger G, Steinert M, Niethammer D, Dopfer R: 8-methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Transplantation 50:807, 1990
12. Vogelsang GB, Wolff D, Altomonte V, Farmer E, Morison WL, Corio R, Horn T: Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transplant 17:1061, 1996
13. Holdiness MR: Clinical pharmacokinetics of clofazimine. A review. Clin Pharmacol 16:74, 1989
14. Mackey JP, Barnes J: Clofazimine in the treatment of discoid lupus erythematosus. Br J Dermatol 91:93, 1974
15. Crovato F, Levi L: Clofazimine in the treatment of annular lupus erythematosus. Arch Dermatol 117:249, 1981
16. Michaelsson G, Molin L, Ohman S, Gip L, Lindstrom B, Skogh M, Trolin I: Clofazimine. A new agent for the treatment of pyoderma gangrenosum. Arch Dermatol 112:344, 1976
17. Brandt L, Gartner I, Nilsson PG, Olofsson T: Pyoderma gangrenosum associated with regional enteritis. Acta Med Scand 201:141, 1977
18. Thomsen C, Rothenborg HW: Clofazimine in the treatment of pyoderma gangrenosum. Arch Dermatol 115:851, 1979
19. Mensing H: Clofazimine in dermatitis ulcerosa (pyoderma gangrenosum). Dermatologica 177:232, 1988
20. Chuaprapaisilp T, Piamphongsant T: Treatment of pustular psoriasis with clofazimine. Br J Dermatol 99:303, 1978
21. Yawalkar SJ, Vischer W: Lamprene (Clofazimine) in leprosy. Lepr Rev 50:135, 1979
22. Moore VJ: A review of the side-effects experienced by patients taking clofazimine. Lepr Rev 54:327, 1983
23. Mansfield RE: Tissue concentrations of clofazimine (B663) in man. Am J Trop Med Hyg 23:1116, 1974
24. Hudson V, Cox F, Taylor L, Guill M, Wray B, Steele J: Pulmonary clofazimine crystals in a child with acquired immunodeficiency syndrome and disseminated mycobacterium avium-intracellulare infection. Pediatr Infect Dis J 7:880, 1988
25. Belaube P, Devaux J, Pizzi M, Boutboul R, Privat Y: Small bowel deposition of crystals associated with the use of clofazimine (Lamprene) in the treatment of prurigo nodularis. Int J Lepr 51:328, 1983
26. Porter DL, Roth MS, McGarigle C, Ferrara JLM, Antin JH: Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330:100, 1994
27. Mitus AJ, Miller KB, Schenkein DP, Ryan HF, Parsons SK, Wheeler C, Antin JH: Improved survival for patients with acute myelogenous leukemia. J Clin Oncol 13:560, 1995
28. Zeis BM, Schulz EJ, Anderson R, Kleeberg HH: Mononuclear leucocyte function in patients with lichen planus and cutaneous lupus erythematosus during chemotherapy with clofazimine. S Afr Med J 75:161, 1989
29. Anderson R, Zeis BM, Anderson IF: Clofazimine-mediated enhancement of reactive oxidant production by human phagocytes as a possible therapeutic mechanism. Dermatologica 176:234, 1988
30. van Rensburg CEJ, Gatner EMS, Imkamp FMJH, Anderson R: Effects of clofazimine alone or combined with dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy. Antimicrob Agents Chemother 21:693, 1982
31. Anderson R, Smit MJ: Clofazimine and B669 inhibit the proliferative responses and Na+, K+-adenosine triphosphatase activity of human lymphocytes by a lysophospholipid-dependent mechanism. Biochem Pharmacol 46:2029, 1993
32. Anderson R: Enhancement by clofazimine and inhibition by dapsone of production of prostaglandin E2 by human polymorphonuclear leukocytes in vitro. Antimicrob Agents Chemother 27:257, 1985
33. 125I-labelled immune complexes by clofazimine treated macrophage cultures. Clin Exp Immunol 48:268, 1982
34. Wadee AA, Kuschke RH, Dooms TG: The inhibitory effects of Mycobacterium tuberculosis on MHC class II expression by monocytes activated with riminophenazines and phagocyte stimulants. Clin Exp Immunol 100:434, 1995
35. Watson S, Auclair LK, Collins FM: The effect of combined chemotherapy on suppressor T-cell activity in Mycobacterium simiae-infected mice. Immunology 43:459, 1981
36. Banerjee DK, Ellard GA, Gammon PT, Waters MFR: Some observations on the pharmacology of clofazimine (B663). Am J Trop Med Hyg 23:1110, 1974
37. Levy L: Pharmacologic studies of clofazimine. Am J Trop Med Hyg 23:1097, 1974
38. Hastings RC, Jacobson RR, Trautman JR: Long-term clinical toxicity studies with clofazimine (B663) in leprosy. Int J Lepr 44:287, 1976
39. Craythorn JM, Swartz M, Creel DJ: Clofazimine-induced bull's-eye retinopathy. Retina 6:50, 1986
40. Ohman L, Wahlberg I: Ocular side-effects of clofazimine. Lancet 2:933, 1975